Factors Affecting Survival in Patients Receiving Radiotherapy for Prostate Cancer Bone Metastasis

Year 2022, Volume: 17 Issue: 2, 90 - 96, 15.07.2022

Selahattin Menteş Feryal Karaca Sıddık Keskin

https://doi.org/10.17517/ksutfd.860872

Abstract

Objective: This study aimed to compare the factors that are thought to affect the survival of patients who received radiotherapy to the metastatic bone in prostate cancers.
Material and Methods: The study included 92 patients who received radiotherapy for prostate cancer bone metastasis.
Results: While death was observed with a rate of 57.1% in patients aged ≤70 years, this rate was determined as 74% in patients aged >70 years. Although there was no statistically significant difference in comparing these values, it was observed that patients aged >70 years tend to have a 2.135 times higher risk of death compared to patients aged ≤70 years (p>0.05). When the survival of patients with visceral organ metastasis and bone metastasis was compared with those with only bone metastasis, a statistically significant result was observed (p<0.01). While all (100%) patients who had bone metastasis with lung metastasis and had bone metastasis with liver metastasis died, the mortality rate decreased to 49.2% in patients with only bone metastasis. The relationship between the radiotherapy portal and mortality was not statistically significant.
Conclusion: A patient’s visceral organ metastasis, marital status, Gleason score at the time of diagnosis, age, and weight affect the survival of patients with prostate cancer treated with radiotherapy to the metastatic bone.

Keywords

Bone metastasis, Prostate cancer, Radiotherapy, Survival

Prostat Kanseri Kemik Metastazına Radyoterapi Uygulanan Hastalarda Sağ Kalımı Etkileyen Faktörler

Abstract

Amaç: Bu çalışmada, prostat kanserlerinde metastatik kemiğe radyoterapi uygulanan hastalarda sağ kalım üzerine etkili olabileceği düşünülen faktörlerin karşılaştırılması amaçlanmıştır.
Gereç ve Yöntemler: Prostat kanserinin kemik metastazı nedeniyle radyoterapi almış olan 92 hasta çalışmaya dahil edilmiştir.
Bulgular: Yetmiş yaşından küçük hastalarda %57.1 oranında ölüm gözlenirken, >70 yaş hastalarda bu oran %74 olarak belirlenmiştir. Bu değerlerin karşılaştırılmasında her ne kadar istatistiksel olarak anlamlı fark görülmese de >70 olan hastaların ≤70 hastalara göre ölüm riskinin 2.135 kat daha yüksek olma
eğiliminde olduğu gözlenmiştir (p>0.05). Visseral organ metastazı ile birlikte kemik metastazı olan hastalarla, yalnız kemik metastazı olan hastaların sağ kalımı karşılaştırıldığında istatistiksel olarak anlamlı sonuç bulunmuştur (p<0.01). Akciğer metastazı ile birlikte kemik metastazı olan ve karaciğer metastazı
ile birlikte kemik metastazı olan hastaların hepsi (%100) ölmüştür, yalnız kemik metastazı olan hastalarda ise ölüm oranı %49.2’ye düşmüştür. Radyoterapi sahası ile ölüm oranı arasındaki ilişki istatistiksel olarak anlamlı bulunmamıştır.
Sonuç: Hastanın visseral organ metastazı, evlilik durumu, tanı anındaki Gleason skoru, yaşı ve kilosu metastatik kemiğe radyoterapi uygulanan prostat kanserli hastaların sağ kalımını etkilemektedir.

Keywords

Kemik metastazı, Prostat kanseri, Radyoterapi, Sağ kalım

References

• Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH et al. Cancer treatment and survivorship statistics CA. Cancer J Clin. 2016;66(4):271–289.
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012. Int J Cancer. 2015;136(5):359–386.
• Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis. 2011;14(2):177–183.
• Zhuo L, Cheng Y, Pan Y, Zong J, Sun W, Xu L et al. Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database. BMJ Open. 2019;9(6):e028214.
• EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2. EAU Guidelines Office, Arnhem, The Netherlands.
• National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Prostate Cancer(Version2.2021).https:// www.nccn.org/professionals/physician_gls/pdf/prostate_blocks. pdf. Accessed 16 March 2021.
• Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12:20-37.
• Kuchuk M, Kuchuk I, Sabri E, Hutton B, Clemons M, Wheatley- Price P. The incidence and clinical impact of bone metastases in non-small cell lung cancer. Lung Cancer. 2015;89:197-202.
• Büyükalpelli R. Prostat kanserinde ağrı ve tedavisi. Üroonkoloji Bülteni. 2009;1:7-13.
• Mayadağlı A, Bulut G, Ekici K. Metastatik Kemik Tümörlerine Yaklaşım. J Kartal TR. 2011;22(1):49-55.
• Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S et al. Extent of disease in recurrent prostate cancer determined by [68Ga] PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. European journal of nuclear medicine and molecular imaging. 2016;43(3):397-403.
• Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162–167.
• Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z,Tilki D et al. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. World J Urol. 2018;36(9):1399– 1407.
• Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF et al. Rates of positive surgical margins and their effect on cancerspecific mortality at radical prostatectomy for patients with clinically localized prostate cancer. Clin Genitourin Cancer. 2019;17(1):130–139.
• Zhao F, Wang J, Chen M, et al. Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients. Clin Trans Med. 2019;8:30.
• Guo Y, Mao S, Zhang A, Wang R, Zhang Z, Zhang J et al. Prognostic significance of young age and non-bone metastasis at diagnosis in patients with metastatic prostate cancer: a SEER population- based data analysis. J Cancer. 2019;10(3):556–567.
• Hartsell WF, Scott CB et al. Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases. Journal of the National Cancer Institute. 2005;97(11):798- 804.